Followers | 144 |
Posts | 27707 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Thursday, October 20, 2005 2:01:24 PM
Predix was expected to raise $55 million on Nasdaq at a company value of $232 million.
Tali Tsipori 20 Oct 05 15:15
Israeli biotechnology company Predix Pharmaceuticals Holdings, which was scheduled to complete the pricing stage for its Nasdaq IPO last night, has apparently been forced to postpone it by one day. Predix was expected to raise $55 million at a company value of $211-253 million (average company value - $232 million). Trading in the company share will therefore begin tomorrow under the PRDX ticker symbol.
Predix will issue five million shares in the $10-12 price range. The underwriters -- UBS Investment Bank, Deutsche Bank Securities, ThinkEquity Partners LLC, and CIBC World Markets Corp. -- will receive an option to buy 750,000 more shares from the company, which would increase the proceeds by $8.3 million.
Predix focuses on the discovery and development of new drugs for treating diseases linked to G-Protein coupled receptors.
Published by Globes [online] - www.globes.co.il - on October 20, 2005
Dubi
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM